Singapore

Singapore

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.69 (2.51 - 2.86) 2019 Modelled IHME
2.67 (2.49 - 2.85) 2018 Modelled IHME
2.66 (2.47 - 2.87) 2017 Modelled IHME
2.65 (2.47 - 2.82) 2016 Modelled IHME
2.65 (2.47 - 2.83) 2015 Modelled IHME
2.66 (2.48 - 2.83) 2014 Modelled IHME
2.69 (2.51 - 2.85) 2013 Modelled IHME
2.73 (2.55 - 2.90) 2012 Modelled IHME
2.77 (2.59 - 2.96) 2011 Modelled IHME
2.81 (2.63 - 3.03) 2010 Modelled IHME
2.85 (2.67 - 3.04) 2009 Modelled IHME
2.9 (2.71 - 3.09) 2008 Modelled IHME
2.95 (2.75 - 3.14) 2007 Modelled IHME
3 (2.79 - 3.20) 2006 Modelled IHME
3.05 (2.82 - 3.27) 2005 Modelled IHME
3.11 (2.87 - 3.32) 2004 Modelled IHME
3.17 (2.93 - 3.38) 2003 Modelled IHME
3.23 (2.99 - 3.45) 2002 Modelled IHME
3.29 (3.02 - 3.54) 2001 Modelled IHME
3.34 (3.05 - 3.61) 2000 Modelled IHME
3.39 (3.12 - 3.66) 1999 Modelled IHME
3.44 (3.18 - 3.70) 1998 Modelled IHME
3.49 (3.23 - 3.75) 1997 Modelled IHME
3.54 (3.28 - 3.81) 1996 Modelled IHME
3.59 (3.31 - 3.87) 1995 Modelled IHME
3.65 (3.39 - 3.93) 1994 Modelled IHME
3.71 (3.44 - 4.01) 1993 Modelled IHME
3.78 (3.50 - 4.09) 1992 Modelled IHME
3.84 (3.55 - 4.19) 1991 Modelled IHME
3.91 (3.60 - 4.32) 1990 Modelled IHME
2.61 (2.08 - 3.19) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.1 (0.08 - 0.14) 2019 Modelled IHME
0.1 (0.08 - 0.13) 2018 Modelled IHME
0.1 (0.08 - 0.14) 2017 Modelled IHME
0.11 (0.08 - 0.14) 2016 Modelled IHME
0.11 (0.08 - 0.15) 2015 Modelled IHME
0.11 (0.08 - 0.15) 2014 Modelled IHME
0.11 (0.09 - 0.14) 2013 Modelled IHME
0.11 (0.09 - 0.14) 2012 Modelled IHME
0.11 (0.09 - 0.14) 2011 Modelled IHME
0.11 (0.08 - 0.14) 2010 Modelled IHME
0.11 (0.09 - 0.15) 2009 Modelled IHME
0.12 (0.09 - 0.15) 2008 Modelled IHME
0.13 (0.10 - 0.17) 2007 Modelled IHME
0.13 (0.10 - 0.17) 2006 Modelled IHME
0.14 (0.11 - 0.18) 2005 Modelled IHME
0.14 (0.11 - 0.18) 2004 Modelled IHME
0.14 (0.11 - 0.18) 2003 Modelled IHME
0.14 (0.11 - 0.18) 2002 Modelled IHME
0.14 (0.11 - 0.18) 2001 Modelled IHME
0.14 (0.11 - 0.19) 2000 Modelled IHME
0.15 (0.11 - 0.19) 1999 Modelled IHME
0.15 (0.12 - 0.20) 1998 Modelled IHME
0.16 (0.13 - 0.21) 1997 Modelled IHME
0.18 (0.14 - 0.23) 1996 Modelled IHME
0.19 (0.15 - 0.25) 1995 Modelled IHME
0.22 (0.17 - 0.28) 1994 Modelled IHME
0.26 (0.20 - 0.33) 1993 Modelled IHME
0.31 (0.24 - 0.40) 1992 Modelled IHME
0.37 (0.28 - 0.48) 1991 Modelled IHME
0.43 (0.33 - 0.57) 1990 Modelled IHME
0.47 (0.32 - 0.66) 2015 Modelled WHO
0.3 2010 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
55 (45 - 66) 2019 Modelled IHME
56 (45 - 66) 2018 Modelled IHME
56 (45 - 66) 2017 Modelled IHME
56 (46 - 66) 2016 Modelled IHME
56 (46 - 66) 2015 Modelled IHME
56 (46 - 66) 2014 Modelled IHME
57 (47 - 66) 2013 Modelled IHME
57 (47 - 67) 2012 Modelled IHME
57 (48 - 67) 2011 Modelled IHME
58 (48 - 67) 2010 Modelled IHME
58 (48 - 68) 2009 Modelled IHME
59 (49 - 68) 2008 Modelled IHME
59 (49 - 68) 2007 Modelled IHME
59 (49 - 69) 2006 Modelled IHME
59 (49 - 69) 2005 Modelled IHME
59 (49 - 69) 2004 Modelled IHME
60 (50 - 69) 2003 Modelled IHME
61 (51 - 70) 2002 Modelled IHME
61 (52 - 70) 2001 Modelled IHME
62 (53 - 71) 2000 Modelled IHME
62 (53 - 71) 1999 Modelled IHME
62 (53 - 71) 1998 Modelled IHME
62 (53 - 71) 1997 Modelled IHME
62 (53 - 71) 1996 Modelled IHME
62 (53 - 71) 1995 Modelled IHME
62 (53 - 71) 1994 Modelled IHME
62 (53 - 71) 1993 Modelled IHME
63 (54 - 72) 1992 Modelled IHME
63 (54 - 72) 1991 Modelled IHME
64 (55 - 72) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
91 2018 Survey/reported WHO/UNICEF
91 2017 Survey/reported WHO/UNICEF
91 2016 Survey/reported WHO/UNICEF
71 2015 Survey/reported WHO/UNICEF
68 2014 Survey/reported WHO/UNICEF
68 2013 Survey/reported WHO/UNICEF
67 2012 Survey/reported WHO/UNICEF
69 2011 Survey/reported WHO/UNICEF
69 2010 Survey/reported WHO/UNICEF
69 2009 Survey/reported WHO/UNICEF
71 2008 Survey/reported WHO/UNICEF
72 2007 Survey/reported WHO/UNICEF
74 2006 Survey/reported WHO/UNICEF
74 2005 Survey/reported WHO/UNICEF
72 2004 Survey/reported WHO/UNICEF
77 2003 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
96 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
96 2014 Survey/reported WHO/UNICEF
97 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
96 2007 Survey/reported WHO/UNICEF
95 2006 Survey/reported WHO/UNICEF
96 2005 Survey/reported WHO/UNICEF
94 2004 Survey/reported WHO/UNICEF
95 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
95 2001 Survey/reported WHO/UNICEF
97 2000 Survey/reported WHO/UNICEF
96 1999 Survey/reported WHO/UNICEF
96 1998 Survey/reported WHO/UNICEF
97 1997 Survey/reported WHO/UNICEF
96 1996 Survey/reported WHO/UNICEF
96 1995 Survey/reported WHO/UNICEF
94 1994 Survey/reported WHO/UNICEF
90 1993 Survey/reported WHO/UNICEF
78 1992 Survey/reported WHO/UNICEF
76 1991 Survey/reported WHO/UNICEF
74 1990 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.58 (0.47 - 0.72) 2019 Modelled IHME
0.57 (0.46 - 0.70) 2018 Modelled IHME
0.55 (0.45 - 0.68) 2017 Modelled IHME
0.54 (0.44 - 0.66) 2016 Modelled IHME
0.53 (0.43 - 0.65) 2015 Modelled IHME
0.52 (0.42 - 0.64) 2014 Modelled IHME
0.51 (0.42 - 0.63) 2013 Modelled IHME
0.51 (0.41 - 0.62) 2012 Modelled IHME
0.5 (0.41 - 0.62) 2011 Modelled IHME
0.5 (0.40 - 0.61) 2010 Modelled IHME
0.49 (0.40 - 0.61) 2009 Modelled IHME
0.49 (0.40 - 0.60) 2008 Modelled IHME
0.49 (0.39 - 0.60) 2007 Modelled IHME
0.49 (0.39 - 0.60) 2006 Modelled IHME
0.48 (0.39 - 0.60) 2005 Modelled IHME
0.48 (0.39 - 0.59) 2004 Modelled IHME
0.48 (0.39 - 0.59) 2003 Modelled IHME
0.47 (0.38 - 0.59) 2002 Modelled IHME
0.47 (0.38 - 0.59) 2001 Modelled IHME
0.47 (0.38 - 0.59) 2000 Modelled IHME
0.47 (0.38 - 0.58) 1999 Modelled IHME
0.47 (0.37 - 0.58) 1998 Modelled IHME
0.47 (0.37 - 0.58) 1997 Modelled IHME
0.46 (0.37 - 0.58) 1996 Modelled IHME
0.46 (0.37 - 0.57) 1995 Modelled IHME
0.46 (0.37 - 0.57) 1994 Modelled IHME
0.47 (0.37 - 0.57) 1993 Modelled IHME
0.47 (0.37 - 0.58) 1992 Modelled IHME
0.47 (0.37 - 0.58) 1991 Modelled IHME
0.47 (0.38 - 0.59) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
42.5 (39.10 - 45.90) 2006 Survey/reported Winslow M et al, 2007

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
29 (20 - 39) 2019 Modelled IHME
29 (20 - 38) 2018 Modelled IHME
29 (20 - 38) 2017 Modelled IHME
29 (20 - 38) 2016 Modelled IHME
29 (20 - 38) 2015 Modelled IHME
28 (20 - 38) 2014 Modelled IHME
28 (19 - 37) 2013 Modelled IHME
28 (19 - 37) 2012 Modelled IHME
27 (19 - 37) 2011 Modelled IHME
27 (18 - 36) 2010 Modelled IHME
27 (18 - 36) 2009 Modelled IHME
26 (18 - 35) 2008 Modelled IHME
26 (18 - 35) 2007 Modelled IHME
26 (18 - 35) 2006 Modelled IHME
26 (18 - 35) 2005 Modelled IHME
26 (18 - 35) 2004 Modelled IHME
25 (17 - 34) 2003 Modelled IHME
25 (17 - 33) 2002 Modelled IHME
24 (17 - 33) 2001 Modelled IHME
24 (16 - 32) 2000 Modelled IHME
24 (16 - 32) 1999 Modelled IHME
24 (16 - 31) 1998 Modelled IHME
24 (16 - 32) 1997 Modelled IHME
24 (16 - 32) 1996 Modelled IHME
24 (16 - 32) 1995 Modelled IHME
24 (16 - 32) 1994 Modelled IHME
24 (16 - 32) 1993 Modelled IHME
23 (16 - 31) 1992 Modelled IHME
23 (16 - 31) 1991 Modelled IHME
23 (15 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.69 (%)
2019
(2.51 - 2.86(%))
IHME
HCV (RNA/cAg+)
0.58 (%)
2019
(0.47 - 0.72(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
502
2019
(420 - 588)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
220
2019
(156 - 287)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.30 (%)
2010, survey/surveillance
WHO WPRO, Woodring J et al, 2017

Prevalence PWID

HCV
0
, latest modelled

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
91 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines